# PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

> **NCT01696565** · PHASE1,PHASE2 · COMPLETED · sponsor: **PhytoHealth Corporation** · enrollment: 32 (actual)

## Conditions studied

- Neoplasm Metastasis
- Neoplasm Recurrence

## Interventions

- **DRUG:** PG2

## Key facts

- **NCT ID:** NCT01696565
- **Lead sponsor:** PhytoHealth Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** 2003-10
- **Final completion:** 2003-10
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01696565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01696565, "PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01696565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*